Evotec SE Board of Directors

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Ms. Aurelie Dalbiez

Ms. Aurelie Dalbiez

Chief People Officer & Member of Management Board

Dr. David Hallet

Dr. David Hallet

Executive Vice President

Dr. Ian M. Hunneyball

Dr. Ian M. Hunneyball

Senior Vice President of Programme Management & Clinical Operations

Mr. Volker Braun

Mr. Volker Braun

Executive VP and Head of Global Investor Relations & ESG

Gabriele Hansen

Gabriele Hansen

Senior VP & Head of Global Corporate Communications & Marketing

Dr. Christian Dargel

Dr. Christian Dargel

EVP Global Head of Legal & Compliance

Dr. Christian Wojczewski

Dr. Christian Wojczewski

Chief Executive Officer

Uwe Andag

Uwe Andag

EVP Head of Metabolic Diseases

Dr. Cord Dohrmann Ph.D.

Dr. Cord Dohrmann Ph.D.

Chief Scientific Officer & Member of Management Board

Ms. Laetitia Rouxel

Ms. Laetitia Rouxel

CFO & Member of Management Board

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.